At a glance
ClinicalIndex Comparison RecordN/ACompleted· 72 enrolled
Drug / intervention
Fimasartandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry
In Brief
An observational study evaluating Fimasartan for Left Ventricular Hypertrophy and Hypertension. Completed, enrolled 72 participants.
Detailed Summary
Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLeft Ventricular Hypertrophy, Hypertension
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
Primary CompletionApr 2017
Study CompletionMay 2017
First PostedJul 2017
TodayJul 2026
First PostedJul 17, 2017
Enrollment StartJun 5, 2012
Primary CompletionApr 30, 2017
Study CompletionMay 30, 2017
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.0 years ago
Interventions
Fimasartandrug
Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.